Professor Faiez Zannad is currently Professor Emeritus of Therapeutics at the Université of Lorraine, France and section editor of the European Society of Cardiology (ESC) Textbook.
Professor Zannad studied and trained at Université de Lorraine, Nancy; Université Claude Bernard, Lyon, France; and Oxford MRC, UK. He has contributed to the evidence supporting modern heart failure therapy, including mineralocorticoid receptor antagonists, beta-blockers, and anticoagulants, as well as in major comorbid conditions in heart failure (such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, and chronic kidney disease). Recently, Professor Zannad has led two European Union granted research programs on omics biomarkers (HOMAGE) and fibrosis as a biological target (FIBROTARGETS).
Previously, Professor Zannad has been the Director of the Inserm Clinical Investigation Centre at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. In addition, he is Past Chairman of both the French Society of Hypertension and the ESC Working Group on Pharmacology and Drug Therapy. He is also the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop: a think tank series of global meetings dedicated to the science of clinical trials.
Over his career, Professor Zannad has published over 800 peer-reviewed articles and numerous books and chapters. In recognition of his work, Professor Zannad has received the 2014 European Society of Hypertension Paul Milliez Award, the 2017 Lifetime Achievement Award from the ESC-HFA, and the 2019 Eugene Braunwald Scholarship.
